FRANKFURT -(Dow Jones)- Bayer Schering Pharma AG, a company belonging to Bayer AG (BAYN.XE), said Monday it has enrolled the first patients in a Phase III trial using florbetaben imaging to detect beta-Amyloid deposits in the brain, a hallmark of Alzheimer’s Disease.

Read more from the original source:
Bayer: To Begin Phase III Florbetaben Trial For Alzheimer’s (Nasdaq)